Cargando…
Immuno-Oncology: Emerging Targets and Combination Therapies
Host immunity recognizes and eliminates most early tumor cells, yet immunological checkpoints, exemplified by CTLA-4, PD-1, and PD-L1, pose a significant obstacle to effective antitumor immune responses. T-lymphocyte co-inhibitory pathways influence intensity, inflammation and duration of antitumor...
Autores principales: | Marshall, Henry T., Djamgoz, Mustafa B. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115503/ https://www.ncbi.nlm.nih.gov/pubmed/30191140 http://dx.doi.org/10.3389/fonc.2018.00315 |
Ejemplares similares
-
Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
por: Kamta, Jeff, et al.
Publicado: (2017) -
The Role of Radiation Oncology in Immuno‐Oncology
por: Meng, Xiangjiao, et al.
Publicado: (2019) -
Immuno-oncology therapy associated thromboembolic events in metastatic renal cell carcinoma
por: Alhamdani, Zein, et al.
Publicado: (2023) -
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
por: Belluomini, Lorenzo, et al.
Publicado: (2022) -
Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology
por: Finotello, Francesca, et al.
Publicado: (2018)